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Cancer cell is the type of cell that is not regulated by the normal cell checkpoints. It shows 
an aberrant cell proliferation and a high metastatic potential. Caner is one of the leading 
causes in human death globally among all diseases. There are more than 100 kinds of 
cancer types, including breast, lung, colorectal, prostate, etc. Currently, surgical method, 
radiation therapy, targeted therapy and chemotherapy have been widely adopted to treat 
cancers depending on the cancer type and their statuses. In breast cancer, there are four 
main types: luminal A, B, triple positive and triple negative based on the receptor: 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor (HER2) status. Among these four subtypes, triple-negative breast cancer (TNBC) 
has the lowest 5-year survival rate and highest recurrence rate1. Currently, there are four 
non-surgical therapies: target therapy, hormonal therapy, immunotherapy, and 
chemotherapy. However, due to the fact that TNBC lacks all three types of receptors, 
hormonal and target therapy are not the options for treating TNBCs. As of 2021, there are 
only two immunotherapeutic drugs approved in treating TNBC, which have to be used in 
combination with other chemotherapeutic drugs2,3. Therefore, chemotherapy remains the 
only non-surgical therapy in treating TNBC. 
 
Anticancer drugs can be (1) cytotoxic (alkylating agent and anti-metabolite), (2) inhibit cell 
growth (mitotic inhibitor) or (3) disrupt enzyme functions (PARP inhibitor or EGFR 
inhibitors). Even though it has been proved that 3D models better mimics in vivo 
conditions, 2D monolayer assay is still used to learn drug efficacies4. Partly due to the 
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reason for its reproducibility. In addition to that, and many estimators can be calculated, 
i.e. IC50 values, maximal inhibition, etc. However, these estimators are usually calculated 
based on the inhibition curve, which can potentially be confounded by the variability of 
cell proliferation rate, cell density and doubling time. Consequently, the mechanism of 
anticancer drugs can be misleading. 
 
In this project, we are introducing a high-throughput method to learn drug efficacies in 
both 2D and 3D by utilizing H33342 and PI stains for live and dead, respectively. We also 
showed how IC50 was confounded by the growth rate and therefore, growth rate inhibition 
should be used in combination to learn drug responses, which potentially decouples the 
effect of different proliferation rate in 2D and 3D. In this study, we studied the drug 
responses of 6 drugs on MDA-MB-231 and MCF-7. From the preliminary results, it was 
shown that during the first 48- and 72-hour treatment, none of the drugs were able to kill 
MDA-MB-231 compared to the initial cell count. However, a decrease in the live cell count 
was observed from 48-hour to 72-hour treatment, implying a longer period observation 
time might be required to further understand the mechanism. In addition to that, MDA-
MB-231 responds to all drugs the same in both 2D and 3D. However, on the contrary, 
MCF-7 showed different drug responses in 2D and 3D. 
In conclusion, we used a high-throughput method to screen 6 drug responses in both 2D 
and 3D. For MDA-MB-231, the drug responses in 2D and 3D were the same while in the 
case of MCF-7, it showed different responses in 2D and 3D. Therefore, to screen a 
chemotherapeutic drug in 3D or not seems in a cell-line dependent manner. For our 
preliminary conclusion, it seems TNBC cells (MDA-MB-231) response the same in both 
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2D and 3D while non-TNBC (MCF-7) responds differently. However, to confirm the trend, 
more repeat data should be collected, and more cell lines should be tested. 
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1 Introduction  
1.1 Background 
Breast cancer is one of the leading causes of cancer-related death in the United States. 
It is estimated that 1/8 females (12.5%) will develop breast cancer in their lifetimes5. There 
are four stages in breast cancer: the earliest stage is stage 0 (carcinoma in situ) and 
ranges from stage I through IV, which stage IV is metastatic and is the most malignant 
and aggressive stage of the diseases. Early detection helps breast cancer patients to 
increase the 5-year survival rate from 75% to 90%1,5. Even though early stage breast 
cancer can be highly curable, but the 5-year survival rate for metastatic breast cancer 
patients is only 20%6. Breast cancer is a heterogeneous disease with multiple subtypes, 
which is characterized by the receptor status, including estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Triple-
negative breast cancer (TNBC) is the subtype that lacks all three types of receptors, and 
among all subtypes, is the most malignant with poorest prognosis clinically, which is 
accountable for 15%-20% of breast cancer patients7,8. Some of common breast cancer 
cell lines with detailed receptor status are listed in Table 1. Moreover, unfortunately, the 
5-year diseases-free survival rate were 57.5% for TNBC patients and 75.3% for Non-
TNBC patients9. While there are various treatments for breast cancer, selection of 
treatment mainly depends on the types of the breast cancer. Current therapeutic 
strategies include surgery, radiotherapy, target therapy, hormonal therapy, 




Subtype Receptor Status Cell Line Examples 
Luminal A   ER+, PR+, HER2- MCF7 
Luminal B (HER2+)  
ER+, PR+, HER2+ 
 
BT474 
HER2 positive ER-, PR-, HER2+ HCC1569 
Basal Like Triple negative MDA-MB-231 
Table 1. 1 Common subtypes of breast cancer cell lines and corresponding receptor status 
 
1.2  Anticancer Treatments  
Surgical and radiotherapeutic methods are commonly used to treat various types of 
cancers, including breast cancer, to remove, destroy, shrink, and contain the growth of 
tumor growth locally. Target and hormonal therapies are used to treat non-TNBC cancer, 
which expresses one of the three receptors. Current target and hormonal includes 
trastuzumab(Herceptin), tamoxifen (Saltamox) and aromatase inhibitor, such as 
anastrozole (Arimidex), exemestane(Aromasin) and letrozole (Femara), etc.  
Immunotherapy is new treatment method that is yet to be explored. As of 2021, there are 
only two immunotherapeutic drugs approved for breast cancer treatment, including 
atezolizumab and pembrolizumab2,3. Even though atezolizumab and pembrolizumab 
showed efficacy in treating TNBCs, these drugs are still suggested to be used in 
combination with other chemotherapeutic drugs. Therefore, to treat TNBC patients, 
chemotherapeutic drugs are still the most frequently used in clinical8. Chemo-drugs are 
usually taken orally or intravenously/intramuscularly, depending on the type and the stage 
of the cancer. Chemotherapeutic drugs can destroy and/or control cancer cells through 
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the body depending on the type. Chemotherapeutic drugs can be further divided into five 
major categories, including alkylating agents, anti-metabolite, mitotic inhibitors, poly ADP-
ribose polymerase (PARP) inhibitors and epidermal growth factor receptor (EGFR) 
inhibitors.  
 
1.3 Chemotherapeutic Drugs  
Alkylating agents were the first non-hormonal compounds to be active against malignant 
cells, including leukemia, lymphoma and breast cancer10. Alkylating drugs are believed 
to exert cytotoxic effects through covalent linkage of alkyl group to DNA10. Thus, prevent 
cell division. Anti-metabolite drugs are also cytotoxic to breast cancer cells, in which they 
work by mimicking a false building block in DNA and RNA synthesis11. With the drugs 
incorporated into the DNA, cells are believed to stop replicating, thus induce apoptosis or 
cell cycle arrest depending on the drugs. Since cancer cells are characterized by their 
uncontrollable ability to grow, divide and spread at the developed or distant sites. Mitotic 
inhibitors are the drugs targeting cancer cell arrest during the mitosis by disrupting 
microtubules12. In addition to these clinically approved drugs in treating TNBC patients, 
more chemotherapeutic drugs that aiming certain over-expressed targets are currently 
under experimental/clinical evaluation.  PARP and EGFR inhibitors are novel drugs to 
treat several kinds of cancer cells, including non-small cell lung cancer cell, breast cancer, 
etc. PARP is a multifunctional enzyme, upon activation, plays a role in pathogenesis of 
various cardiovascular and inflammatory diseases. At the same time, it is also known for 
its ability to repair single strand damaged DNA13,14. In TNBCs, EGFR is usually 
overexpressed and thus becomes a potential therapeutic target. There are two types of 
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EGFR inhibitors, small molecular tyrosine kinase inhibitor (TKI) and monoclonal antibody 
(mAb) for treatment of cancers, including non-small cell lung cancer, colorectal cancer 
and breast cancer6. Table 2. summarizes the current clinically approved 
chemotherapeutic drugs in treating TNBCs.  
 






























EGFR Inhibitor6 N/A Under development 




1.4 In vitro Microenvironments and Quantification 
The development and utilization of models that physiologically recapitulate in vivo 
condition is emerging and is believed to be essential in understanding the 
pathophysiology of tumor cells, and to discover new anti-cancer drugs. As a result, 
models that mimic the in vivo tumor microenvironment are developed, including spheroids 
and organoids4,15,16. 3D model is able to mimic cell-cell interaction, cell-ECM interaction, 
oxygen and nutrient gradients, variable stiffness and cell polarity, which are all lacked in 
2D monolayer culture15,17–20. Such characteristics of 3D model better mimics the 
microenvironment where cells reside in tissues16. Thus, these models can bridge the gap 
between in vitro 2D cultures and expensive in vivo animal studies. However, even though 
3D spheroids/organoids better mimics in vivo conditions, current methods are bulk 
measurements. Up to date, most cytotoxicity assays are indirect measurement (MTT/HTT 
assay, BrdU assay and cellular ATP levels), which lacks validation and requires 
normalizations. 
 
1.5 IC50 as an Indicator of Drug Responses 
As aforementioned, 3D is believed to bridge the gap between in vitro and in vivo. Prior to 
clinical trials, drugs are screened both in vitro and in vivo. Inhibition curve is used to study 
the effects of drug-treated conditions relative to drug-free conditions. From the inhibition 
curve, several estimators can be calculated to study the drug efficacy, which are IC50 (half 
maximal inhibitory concentration): measures the concertation of a substance is needed 
to inhibit 50% of a given biological process; and Emax (maximal inhibition), which 
measures the maximal ability of a drug to inhibit cell growth. The advantage of those 
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parameters is that both IC50 and Emax can estimate the efficacy of various drugs within a 
system. However, IC50 and Emax are easily being impacted by the experimental conditions, 
therefore comparing IC50 and Emax in different experiment and setups is more challenging. 
 
1.6 Project Overview 
In the present study, we introduce a high-throughput fluorescent imaging system that was 
previously developed by our lab to monitor drug treatment on MDA-MB-231 and MCF-7 
in both 2D and 3D cell cultures on a single-cell level. 6 anti-TNBC chemotherapeutic drugs 
were selected with various concentration (0.1 mM to 1 nM). Among the chosen drugs, 
there were 2 FDA unapproved drugs and 4 FDA approved drugs. Both cell lines were 
exposed to drugs for 48 hour and 72 hours to learn the mechanism of the drugs. To take 
the doubling time into account, the live, and dead cell count 0 hour prior to treatment were 
recorded by utilizing Hoechst 33342 nucleic stain(H33342) and propidium iodide (PI) stain.  
 
After the information collected, the drug-response curve is then plotted to learn the drug 
efficacy in treating MDA-MB-231, which is a TNBC cell line and MCF-7, which is a non-
TNBC. The IC50 and Emax were calculated to further understand the potency of drugs. As 
the IC50 and Emax can be easily confounded by the variability cell proliferation rate, we 
also graphed growth rate inhibition, which we used to compare the 48-hour and 72-hour 




Given the multiplex advantage of our algorithm, we further learned the cell viability (live 
cell/ total cells) in each condition and then compared the viability under different drugs, 




2 Material and Methods 
2.1 Materials 
2.1.1  Compounds and reagents 
The drugs were obtained from Selleckchem. The collection includes 10 drugs, all 
maintained at 10mM in DMSO. Hoechst 33342 was purchased from Invitrogen and 
Propidium Iodide(PI) was purchased from ThermoFisher. 
Reagent Source 
Corning® Collagen I, High 
Concentration, Rat Tail 
CORNING 
Hoechst 33342 (H33342) 
Thermo Fisher 
Scientific 

























MDA-MB-231 and MCF-7 were obtained from the ATCC. Both cells were cultured in 
DMEM with 1% (v/v) Penicillin-Streptomycin and 10% (v/v) FBS. 
Cell line Subtype [19] Source 
MCF7 Luminal A American Type Culture Collection 
MDA-MB-231 Triple negative American Type Culture Collection 
Table 2. 3 Cell lines used in our drug response testing experiment  
 
2.1.3 Cell culture in 2D and 3D 
MCF-7 and MDA-MB-231 were maintained as monolayer cultures in 10-cm dishes in the 
media described above in an incubator at 37 °C. Prior to preparing cell cultures in 2D and 
3D, cells were trypsinized and collected the supernatant for cell counting. To count the 
cell density, 10 µL of cell solution was stained 30 µL stain (1%(v/v) Hoechst and 1%(v/v) 
PI) in triplicates. For a better counting result, the plate was shaken with 300 rpm for 5 
minutes and then leave on the shaker for 20 minutes at the room temperature before 15-
minute incubation.  
To prepare 3D cultures for high-throughput screening, cells were seeded at 2000 
cells/well in DMEM (as described above) and 2.5 mg/ml Collagen type I , which was 




For 2D high-throughput screening, cells were cultured in the same media, same cell 
concentration and the same kind of 96-well plate. Cell viability was checked using the 
same stain as described above. 
2.1.4 Cytotoxicity assay 
All drugs were pre-diluted to 10mM solution in DMSO or DI water (based on the 
manufacture’s recommendation) as solvent stored at -80 °C. Cells were plated as 
described for 2D or 3D culture, and then treated with compound at the concentration 
mentioned above for 48 or 72 hours. To prepare the final concentration, compounds 
were serial diluted into the final concentration (0.01 mM to 1 nM). To quantify cell 
viability, cells were stained as described above for 1-hour incubation. Due to the 
diffusivity, 25 µL and 50 µL was added to each well in 2D and 3D culture respectively.  
 
2.2 Image processing 
2.2.1  Immunofluorescent analysis of 2D and 3D cultures.  
Both 2D and 3D were stained the same way (H33342 and PI). After stained, the plate 
was imaged under two fluorescent channels (DAPI and TRITC) using a 2X objective, 
which gives a full view of each well.  
 
2.2.2  Cell Counting and Algorithm 
After the images were obtained, a detection algorithm was used to identify the objects 
based on the three properties, including H33342 intensity, PI intensity and cell 
morphology. This algorithm is a novel way of tracking cells and eliminate the duplicated 
detections under different channels. Each object’s H33342 intensities, PI intensities, 
11 
 
positions in cartesian coordinates, distance from the bottom and the radius of the 
signals to the center of the well was recorded for further analysis. To get accurate cell 
counting and further eliminate the noises, a gating process was employed to assure the 
quality of the data. All codes were written as MATLAB script. 
3 Results 
3.1 H33342 vs PI intensity map shows consistent two population to separate 
live and dead cells 
 
Figure 3. 1 Gating map for live and dead index (LDI) cell counting. (a) H33342 vs PI intensity map; 
(b) The corresponding overlapping validation image. 
Figure 3.1(a) is a typical gating map that shows the live and dead cell count (LDI) within 
each well. Since H33342 is a nucleic stain, which can label all cells, regardless of live or 
dead. Therefore all objects have some extent of H33342 intensity. However, PI is a huge 
molecule that is only permeable to dead cells, therefore, only dead cells have PI intensity. 
As shown in Figure 3.1 (a), there are two major populations: green for live cells and red 
for dead cells. Each time, the live and dead cells are selected in different polygons that is 
defined by the user. All the points that are neither in the green nor the red circle will be 
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recognized as noise, which will not be counted when outputted. Figure 3.1(b) shows the 
corresponding validation image. The green dots are the points in the green circle. Given 
the (x,y) coordinates of each point, the overlapping image, therefore, is created for visual 
validation. As shown in Figure 3.1(b), the bulk mass is successfully recognized as noises 
and eliminated. Therefore, the gating method is used to analyze drug treatment data. 
 
3.2 Taxol treatment over MDA-MB-231 and MCF-7 in 2D and 3D 
 
 
Figure 3. 2 Inhibition curve of Taxol treatment on MDA-MB-231. The line in each plot is the average 
line of the three repeats. Taxol treatment on MDA-MB-231 in 2D for 48hr; (b) Taxol treatment on 
MDA-MB-231 in 2D for 72hr; (c) Taxol treatment on MDA-MB-231 in 3D for 48hr; and (d) Taxol 
treatment on MDA-MB-231 in 3D for 72hr.  
Taxol is a chemotherapeutic drug that has various application in treating cancers, 









inhibitor, which functions by disrupting microtubules and thus interferes mitosis12. For 
each concentration, the live cell count is calculated from the GUI mentioned in the earlier 
section. To get the inhibition curve (relative cell count), the cell count in treated conditions 
is normalized by the drug-free condition. When MDA-MB-231 is treated by taxol for 48hr, 
both 2D and 3D showed similar average line as shown in Figure 3.2 (a) and (c). However, 
from Figure 3.2(a) and (c), even though the trend of the average line is similar in 2D and 
3D, their maximal inhibition rate is different, i.e. Emax (2D) = 67.3% and Emax (3D) =39%. 
For 72-hour treatment data, similar trend between 2D and 3D is observed, as shown in 
Figure 3.2 (b) and (d), respectively. The Emax (2D) = 72% and Emax (3D) =60%. When 
compare the 48-hour and 72-hour within the same microenvironment (2D and 3D), 72-








Figure 3. 3 Inhibition curve of Taxol treatment on MCF-7. The line in each plot is the average line of 
the three repeats. (a)Taxol treatment on MCF-7in 2D for 48hr; (b) Taxol treatment on MCF-7in 2D for 
72hr; (c) Taxol treatment on MCF-7 in 3D for 48hr; and (d) Taxol treatment on MCF-7in 3D for 72hr.  
 
Taxol treatment over MCF-7 is shown in Figure 3.3. Similar to MDA-MB-231 treatment, 
at both treatment time points, MCF-7 response to Taxol is very similar. However, a big 
difference in Emax value is observed between 2D and 3D. The Emax for 48hr-treatment 2D 
and 3D is 74.0% and 27.7%, for 72hr-treatment 2D and 3D is 88.0% and 49.3% 
respectively. As shown in Figure 3.4, there was a significant difference between 2D and 
3D in Emax in both MDA-MB-231 and MCF-7. Besides the Emax, another commonly used 







Figure 3. 4 Maximal inhibition of Taxol treatment over MDA-MB-231 and MCF-7. (a) Maximal 
inhibition of Taxol over MDA-MB-231 in 48hr; (b) Maximal inhibition of Taxol over MDA-MB-231 in 
72hr; (c) Maximal inhibition of Taxol over MCF-7 in 48hr; (d) Maximal inhibition of Taxol over MCF-
7 in 72hr; Students’ t-test is used to calculate the statistics and sample size(N) = 3 for each of the 
bar plot. The value is mean ± SEM. 
 
3.3 IC50 value as an indicator of drug potency 
 
Half maximal inhibitory concentration (IC50) is a measurement of the potency of a 
substance in inhibiting a specific biological or biochemical function. In vitro, IC50 measures 
the concentration of a substance (i.e., drug, inhibitors, etc.) is needed to inhibit 50% of a 





Figure 3. 5 IC50 of Taxol treatment over MDA-MB-231 and MCF-7. (a) IC50 of Taxol over MDA-MB-
231 in 48hr; (b) IC50 of Taxol over MDA-MB-231 in 72hr; (c) IC50 of Taxol over MCF-7 in 48hr; (d) IC50 
of Taxol over MCF-7 in 72hr; Students’ t-test is used to calculate the statistics and sample size(N) 
= 3 for each of the bar plot. The value is mean ± SEM. 
 
As shown in Figure 3.4 (a) and (b), the IC50 values of Taxol over MDA-MB-231 does not 
show any difference between 2D and 3D in both 48-hour and 72-hour treatment. Figure 
3.4 (c) and (d) shows the IC50 value of Taxol over MCF-7, similar to the MDA-MB-231, 
there’s no statistical difference between 2D and 3D. However, as aforementioned, the 






statistical different in the values in MDA-MB-231 and in MCF-7. Table 3.1 summarizes 















48 14.7 67.3 32.1 59% 
72 5.9 75.3 5.5 42.5 
MCF-7 
48 5.4 74.0 5.3 27.7 
72 2.4 88.0 3.0 49.3 
Table 3. 1 Summary of the discrepancy between IC50 and Emax between 2D and 3D 
 
3.4 Growth rate measures the drug response and corrects the confounders that 
caused by cell proliferation rate. 
 
It has been previously shown that the IC50 and Emax values can be confounded by the 
variability in the cell proliferation rate, which can be caused by the cell density, media 
composition and the biological difference in cell doubling time. Therefore, it was 
suggested that using the growth rate to evaluate the drug response potentially corrects 
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MB-231 












Table 3. 2 Cell Count in each treatment conditions. Values are Mean ± SEM 
Table 3.2 summarizes the cell count in each condition. In the highest dosage treatment 
condition, the cell counts in 2D and 3D are similar in both cell lines. Given that they were 
seeded at the same cell count initially, the efficacy in inhibiting cell growth from time 0 to 
the time t should be the same. However, as the inhibition curve is normalized by the drug-
free conditions and there’s a different growth rate, the efficacy appears to be different. As 
shown in Figure 3.3, Taxol seems more effective in inhibiting both cell lines in 2D and 3D, 
however, such effects could be confounded by the variability in the rate of cell proliferation. 




3.5 Growth rate measures the drug response and corrects the confounders that 
caused by cell proliferation rate. 
 
As aforementioned, there is a difference in the cell proliferation rate in 2D and 3D and the 
inhibition curve could be hugely impacted by the variability in cell proliferation rates, which 
is caused by cell density, media composition and cell doubling time21. Therefore, a new 
factor that can decouple these effects is needed. Growth inhibition rate measures the 
proliferation rate from pre-treatment (the 0 hour treatment) to certain treatment time can 
potentially solve the problem. Here, the growth rate inhibition (GRI) is defined as 𝑁𝑡
𝑁0
− 1, 
where Nt is the live cell count at time t post-treatment and N0 is the live cell count at time 
0 post-treatment. By using the method, the inhibition can be divided into three categories: 
if 1< GRI <GRIdrug-free, then it’s partial inhibition; if GRI =0, then it’s total inhibition and if 
GRI <0, it induces cell death. By using the method, the effects of growth rate can be 




Figure 3. 6 Growth inhibition curve of Taxol treatment on MDA-MB-231; (a) Taxol treatment on 
MDA-MB-231 in 2D for 48hr; (b) Taxol treatment on MDA-MB-231 in 3D for 48hr; (c) Taxol treatment 
on MDA-MB-231 in 2D for 72hr; and (d) Taxol treatment on MDA-MB-231 in 3D for 72hr. The red 
dotted line is the pre-treatment cell count. 
As shown in Figure 3.6 (a) and (b), the growth rate in drug-free in 2D and 3D differs 
hugely, however, the growth rate of highest Taxol concentration treated condition is very 
similar in 2D and 3D. Similar to that of 48-hour treatment, 72-hour treatment shows 
similar proliferation rate in higher Taxol treatment conditions between 2D and 3D. 
Interestingly, Taxol, as a mitotic inhibitor, is believed to prevent cell proliferation by 
disrupting microtubule formation and thus induce cell death. However, at all conditions, 
the growth rate is always a positive number, which means that Taxol only slows down 







Figure 3. 7 Growth inhibition curve of Taxol treatment on MCF-7; (a) Taxol treatment on MDA-MB-
231 in 2D for 48hr; (b) Taxol treatment on MDA-MB-231 in 3D for 48hr; (c) Taxol treatment on MDA-
MB-231 in 2D for 72hr; and (d) Taxol treatment on MDA-MB-231 in 3D for 72hr. The red dotted line 
is the pre-treatment cell count. 
Similar to the pattern in MDA-MB-231, MCF-7 also showed differences in the cell 
proliferation in 2D and 3D, but in a greater magnitude. Figure 3.7 (b) and (d) shows a 
huge difference in the cell proliferation in drug-free conditions, however, their relative 
growth rate at higher Taxol concentration shows a similar rate. Therefore, growth 
inhibition curve decouples the effects of the variability of proliferation in 2D and 3D.  
 








Figure 3.8 Live cell count change from 48-hour to 72-hour Taxol treatment under 2D and 3D; (a) 
MDA-MB-231 and (b) MCF-7 
Figure 3.8 (a) shows a decrease in the MDA-MB-231 live cell count from 48-hour to 72-
hour Taxol treatment in both 2D and 3D. The cell count change decreases except the 
lowest Taxol concentration (at Log[Concentration]=-6) and drug-free conditions, but as 
shown in Figure 3.6 (b) and (d), the cell count of 72-hour treatment is still higher than that 
of the 0-hour treatment, therefore, Taxol combats the MDA-MB-231 proliferation and 
within the first 72- hour treatment time, the cell proliferation rate exceeds the Taxol 
inhibition ability.  
However, Figure 3.8 (b) shows a different pattern, MCF-7, when treated in 3D, shows a 
quite large decrease in the live cell count; however, in 2D, the live cell count change was 





3.7 Using growth rate as an indicator to study drug treatment on MDA-MB-231 
and MCF-7 
Therapy Regimen Agent 
Growth Rate at 
10 µm (72hr 
Treatment) 
Growth Rate at 
10 µm (72hr 
Treatment) 




Methotrexate* + + + 0 
5-Flourouracil 
(5-FU) * 
+ + + 0 
Mitotic 
Inhibitor12 
Taxol* + + 0 - 
Vinblastine 
Sulfate* 
+ + 0 - 
PARP 
Inhibitor13,14 
Afatinib# - - - - 
EGFR 
Inhibitor6 
Iniparib# + + + + 
Table 3. 3 Summery of the growth rate of drug treatment on MDA-MB-231 and MCF-7; * stands for 
clinically approved drugs; # stands for clinically unapproved drugs; + means partial inhibition; 0 
means total inhibition; and – means cell death 
Table 3.3 summarizes the growth rate of different drug treatment effects on MDA-MB-231 
and MCF-7. Surprisingly, regardless of the drug type, MDA-MB-231 showed similar 
growth rate inhibition throughout the treatment under 2D and 3D while MCF-7 showed 
micro-environment dependent responses. In addition to that, drugs that are believed to 
24 
 
be cytotoxic did now show much killing effects against MDA-MB-231, i.e. Methotrexate 
and 5-FU. Almost all drugs failed to induce MDA-MB-231 death, except afatinib, which 
failed clinically due to high cytotoxicity22. In the case of MCF-7, drug mechanism shows 
different responses in 2D and 3D, which might indicate drug treatment on MCF-7 is in an 
environment-dependent manner, but not MDA-MB-231. 
 
4 Conclusions 
In conclusion, from our drug responses data on MCF-7 and MDA-MB-231 cells, we 
obtained new insights about the difference of cell growth and death pattern in 2D and 3D 
in vitro. In addition, even though the IC50 values in 2D and 3D are very close to each other, 
their maximal inhibitory effects may var a lot as summarized in Table 3.2 under Taxol 
treatment. Moreover, the cell count at the maximum Taxol dosage were similar in different 
microenvironments in both MDA-MB-231 and MCF-7. However, due to the difference in 
the cell growth pattern in 2D and 3D, the inhibitory curve maybe confounded by the 
variability in the rates of cell proliferation, which is caused by the cell density, media 
composition and the different doubling time. Therefore, to use the growth rate curve as a 
substitute can potentially decouple the growth effects in different environments.  
The growth rate graph gives more information than the inhibitory curve. For example, if 
the value is greater than 0, but less than the GRdrug-free, it means partial inhibition; if it 
equals 0, then it’s total inhibition while induce cell death if it’s less than 0. In addition to 
that, by using the single-cell-level analysis, we were able to learn when the cytotoxicity 
started to show effects in different cell lines.  
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Taxol, instead of killing cells, was able to prevent cell proliferation. It seems to have 
cytotoxic effects over both cell lines, but such effects only showed after cells were 
exposed to drug for 48 hours and was in a micro-environment independent for MDA-MB-
231 and dependent for MCF-7.  
We further tested the drug effects on 5 other drugs, which belonged to 4 different 
categories, including mitotic inhibitors, anti-metabolite, PARP inhibitor and EGFR 
inhibitors using the growth rate inhibition curve. We found that when MDA-MB-231 were 
treated with different drugs, 2D and 3D growth inhibition were very similar to each other 
while MCF-7 showed totally different drug responses in 2D and 3D. 
In the future, to confirm the preliminary results, more biological repeats should be done 
on both cell lines. In addition, to learn the relation of the dependence of the drug treatment, 
more cell lines should be tested to confirm the general trend. Moreover, to better learn 
the how cells happen, more biomarkers should be added for a more comprehensive 
analysis. 
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